Pfizer Inc. $PFE Stock Position Boosted by Coldstream Capital Management Inc.

Coldstream Capital Management Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 27.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 147,793 shares of the biopharmaceutical company’s stock after buying an additional 31,497 shares during the period. Coldstream Capital Management Inc.’s holdings in Pfizer were worth $3,766,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. State Street Corp increased its stake in shares of Pfizer by 0.9% during the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after acquiring an additional 2,786,098 shares during the period. Norges Bank acquired a new stake in Pfizer in the second quarter worth approximately $2,270,157,000. Northern Trust Corp lifted its position in Pfizer by 1.4% in the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after purchasing an additional 869,175 shares during the period. Fisher Asset Management LLC boosted its stake in Pfizer by 1.9% during the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock valued at $1,255,860,000 after purchasing an additional 897,786 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Pfizer by 2.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after purchasing an additional 1,135,457 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

PFE opened at $27.33 on Thursday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The firm has a market cap of $155.38 billion, a PE ratio of 20.09 and a beta of 0.47. The business has a fifty day simple moving average of $26.61 and a 200-day simple moving average of $25.57. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period in the previous year, the firm earned $0.63 earnings per share. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on PFE shares. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Royal Bank Of Canada started coverage on shares of Pfizer in a research report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price target on the stock. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a report on Monday, March 2nd. Finally, HSBC raised their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.14.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase‑2 win for atirmociclib: Pfizer reported positive topline results from the randomized FOURLIGHT‑1 study showing its next‑generation CDK4 inhibitor plus fulvestrant met the primary endpoint and reduced risk of progression or death (~40%). The result strengthens Pfizer’s oncology pipeline and positions atirmociclib as a potential successor/competitive option to existing CDK4/6 therapies. Pfizer Announces Positive Topline Phase 2 Results for Atirmociclib
• Positive Sentiment: Analyst upgrade/price‑target raise: HSBC raised its price target on PFE to $32 and maintained a Buy rating, giving investors an incremental valuation tailwind and signaling analyst confidence in Pfizer’s medium‑term outlook. HSBC Raises Price Target on Pfizer
• Neutral Sentiment: Early liver program progress: Pfizer advanced a Phase‑1 study of PF‑07328948 (liver indication), an early readout that modestly adds breadth to the pipeline but is unlikely to drive material near‑term revenue given its very early stage. Pfizer Advances Early PF-07328948 Liver Study
• Neutral Sentiment: Market/commentary noise: Media/analyst chatter (including TV commentary and bullish opinion pieces) is drawing attention to Pfizer’s broad pipeline and long‑term potential, but these are sentiment drivers rather than new clinical or commercial facts. Expect short‑term volatility around headlines. Jim Cramer Notes Pfizer Has “Got a Lot of Stuff in the Pipeline”
• Negative Sentiment: Study termination in melanoma: Pfizer ended a Phase‑1 study of PF‑08046031 in early‑stage melanoma, trimming one oncology program. While not expected to be material to top‑line forecasts, it marginally reduces pipeline optionality and is a near‑term negative datapoint for investors focused on oncology depth. Pfizer Ends Early-Stage Melanoma Study

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.